Abstract

Purpose: To investigate the prognostic significance of ribonucleotide reductase small subunit M2 (RRM2) in low- and intermediate-risk prostate cancer (PCa). Materials and methods: A retrospective outcome study was conducted on 164 eligible PCa samples from the City of Hope (n = 90) and the Taipei Medical University (n = 74). The RRM2 protein levels were detected by immunohistochemistry. Biochemical recurrence was assessed using Kaplan-Meier and Cox proportional hazard analyses. Cell invasion assays, Ras/Raf, and matrix metallopeptidase 9 activities were determined to evaluate the role of RRM2 on invasiveness of PCa. Results: Expression of RRM2 was significantly increased in patients with higher Gleason score, who had advanced T stage, and who were margin/capsule positive (P-, capsule-, and stage T1-T2. In patients with Gleason score 4 to 7, the risk of recurrence was proportional to RRM2 protein levels. The prognostic performance of RRM2 was superior to that of pathoclinical factors, including margin/capsule status and T stage. An in vitro study demonstrated that RRM2 could promote tumor invasion activities in PCa cell lines. Suppression of RRM2 reduced the Ras/Raf and matrix metallopeptidase 9 activities. Conclusion: RRM2 plays a critical role in proliferation and invasion of PCa. Adding RRM2 as a biomarker in clinical assessments may increase model precision in predicting recurrence in patients with low-risk PCa.

Original languageEnglish
JournalUrologic Oncology: Seminars and Original Investigations
Volume32
Issue number1
DOIs
Publication statusPublished - Jan 2014

Fingerprint

Prostatic Neoplasms
Recurrence
Capsules
Neoplasm Grading
Metalloproteases
ribonucleotide reductase M2
Proteins
Retrospective Studies
Biomarkers
Immunohistochemistry
Outcome Assessment (Health Care)
Cell Line
Neoplasms

Keywords

  • Biochemical recurrence
  • Gleason score
  • Prognostic biomarker
  • Prostate cancer
  • Ribonucleotide reductase M2

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers. / Huang, Yasheng; Liu, Xiyong; Wang, Yuan Hung; Yeh, Shauh Der; Chen, Chi Long; Nelson, Rebecca A.; Chu, Peiguo; Wilson, Timothy; Yen, Yun.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 32, No. 1, 01.2014.

Research output: Contribution to journalArticle

@article{be7a3b500ee848f68767d04f402934fe,
title = "The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers",
abstract = "Purpose: To investigate the prognostic significance of ribonucleotide reductase small subunit M2 (RRM2) in low- and intermediate-risk prostate cancer (PCa). Materials and methods: A retrospective outcome study was conducted on 164 eligible PCa samples from the City of Hope (n = 90) and the Taipei Medical University (n = 74). The RRM2 protein levels were detected by immunohistochemistry. Biochemical recurrence was assessed using Kaplan-Meier and Cox proportional hazard analyses. Cell invasion assays, Ras/Raf, and matrix metallopeptidase 9 activities were determined to evaluate the role of RRM2 on invasiveness of PCa. Results: Expression of RRM2 was significantly increased in patients with higher Gleason score, who had advanced T stage, and who were margin/capsule positive (P-, capsule-, and stage T1-T2. In patients with Gleason score 4 to 7, the risk of recurrence was proportional to RRM2 protein levels. The prognostic performance of RRM2 was superior to that of pathoclinical factors, including margin/capsule status and T stage. An in vitro study demonstrated that RRM2 could promote tumor invasion activities in PCa cell lines. Suppression of RRM2 reduced the Ras/Raf and matrix metallopeptidase 9 activities. Conclusion: RRM2 plays a critical role in proliferation and invasion of PCa. Adding RRM2 as a biomarker in clinical assessments may increase model precision in predicting recurrence in patients with low-risk PCa.",
keywords = "Biochemical recurrence, Gleason score, Prognostic biomarker, Prostate cancer, Ribonucleotide reductase M2",
author = "Yasheng Huang and Xiyong Liu and Wang, {Yuan Hung} and Yeh, {Shauh Der} and Chen, {Chi Long} and Nelson, {Rebecca A.} and Peiguo Chu and Timothy Wilson and Yun Yen",
year = "2014",
month = "1",
doi = "10.1016/j.urolonc.2013.08.002",
language = "English",
volume = "32",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers

AU - Huang, Yasheng

AU - Liu, Xiyong

AU - Wang, Yuan Hung

AU - Yeh, Shauh Der

AU - Chen, Chi Long

AU - Nelson, Rebecca A.

AU - Chu, Peiguo

AU - Wilson, Timothy

AU - Yen, Yun

PY - 2014/1

Y1 - 2014/1

N2 - Purpose: To investigate the prognostic significance of ribonucleotide reductase small subunit M2 (RRM2) in low- and intermediate-risk prostate cancer (PCa). Materials and methods: A retrospective outcome study was conducted on 164 eligible PCa samples from the City of Hope (n = 90) and the Taipei Medical University (n = 74). The RRM2 protein levels were detected by immunohistochemistry. Biochemical recurrence was assessed using Kaplan-Meier and Cox proportional hazard analyses. Cell invasion assays, Ras/Raf, and matrix metallopeptidase 9 activities were determined to evaluate the role of RRM2 on invasiveness of PCa. Results: Expression of RRM2 was significantly increased in patients with higher Gleason score, who had advanced T stage, and who were margin/capsule positive (P-, capsule-, and stage T1-T2. In patients with Gleason score 4 to 7, the risk of recurrence was proportional to RRM2 protein levels. The prognostic performance of RRM2 was superior to that of pathoclinical factors, including margin/capsule status and T stage. An in vitro study demonstrated that RRM2 could promote tumor invasion activities in PCa cell lines. Suppression of RRM2 reduced the Ras/Raf and matrix metallopeptidase 9 activities. Conclusion: RRM2 plays a critical role in proliferation and invasion of PCa. Adding RRM2 as a biomarker in clinical assessments may increase model precision in predicting recurrence in patients with low-risk PCa.

AB - Purpose: To investigate the prognostic significance of ribonucleotide reductase small subunit M2 (RRM2) in low- and intermediate-risk prostate cancer (PCa). Materials and methods: A retrospective outcome study was conducted on 164 eligible PCa samples from the City of Hope (n = 90) and the Taipei Medical University (n = 74). The RRM2 protein levels were detected by immunohistochemistry. Biochemical recurrence was assessed using Kaplan-Meier and Cox proportional hazard analyses. Cell invasion assays, Ras/Raf, and matrix metallopeptidase 9 activities were determined to evaluate the role of RRM2 on invasiveness of PCa. Results: Expression of RRM2 was significantly increased in patients with higher Gleason score, who had advanced T stage, and who were margin/capsule positive (P-, capsule-, and stage T1-T2. In patients with Gleason score 4 to 7, the risk of recurrence was proportional to RRM2 protein levels. The prognostic performance of RRM2 was superior to that of pathoclinical factors, including margin/capsule status and T stage. An in vitro study demonstrated that RRM2 could promote tumor invasion activities in PCa cell lines. Suppression of RRM2 reduced the Ras/Raf and matrix metallopeptidase 9 activities. Conclusion: RRM2 plays a critical role in proliferation and invasion of PCa. Adding RRM2 as a biomarker in clinical assessments may increase model precision in predicting recurrence in patients with low-risk PCa.

KW - Biochemical recurrence

KW - Gleason score

KW - Prognostic biomarker

KW - Prostate cancer

KW - Ribonucleotide reductase M2

UR - http://www.scopus.com/inward/record.url?scp=84890673363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890673363&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2013.08.002

DO - 10.1016/j.urolonc.2013.08.002

M3 - Article

VL - 32

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 1

ER -